Gapping down
In reaction to disappointing earnings/guidance:
- OGI -6.6%, CETV -1.8%, NVS -1.5%, CCK -1.3%, CIT -1%, CBSH -0.8%
Other news:
- ACAD -10.7% (Phase 3 study did not achieve statistical significance on primary endpoint; also announces FDA acceptance of sNDA filing for NUPLAZID)
- CTSO -9.9% (stock offering; also guides Q2 revs slightly above consensus; REFRESH 2-AKI trial may restart this qtr)
- KNSA -7% (commences $100 mln stock offering)
- PIRS -5.8% (discloses partial clinical hold on phase 1 studies of PRS-343)
- QIWI -2.5% (announces offering by selling stockholders)
- VXX -2.4% (trading lower with futures up in pre-mkt)
Analyst comments:
- MDRX -3% (downgraded to Sell from Neutral at Goldman)
- IHRT -2.1% (downgraded to Underweight from Neutral at JP Morgan)
- BHP -1.2% (downgraded to Neutral from Buy at Citigroup)
- OC -0.6% (downgraded to Hold from Buy at The Benchmark Company)